Enhabit, Inc. Hits New 52-Week High of $13.64, Reflecting Strong Growth

Enhabit, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 13.64 on February 23, 2026. This achievement underscores the company's strong performance over the past year, with a remarkable increase of 41.67%, significantly outpacing the S&P 500's growth of 12.95% during the same period. Enhabit’s financial metrics reflect a robust market position, with a price-to-earnings (P/E) ratio of 14.00, indicating a favorable valuation relative to its earnings. The company maintains a healthy debt-to-equity ratio of 0.73, showcasing its ability to manage debt effectively. Additionally, Enhabit has demonstrated impressive growth in net sales, with an annual growth rate of 301.12%, and operating profit growth of 79.91%. The company’s operational efficiency is further highlighted by its strong EBIT to interest ratio of 30.30, suggesting a solid capacity to service its debt. With a market capitalization of USD 561 million, Enhabit continues to establish itself as a notable player in its industry.